CD8A and melanoma: Moreover, we similarly identified correlations between increased CD8+ activation/exhaustion ratio (Relative CD8+ activation) in melanoma metastases and improved survival and RECIST following BRAFi therapy, as well as decreased cell proliferation (Ki67 expression), suggesting that T cell activation status may not only predict clinical outcomes but also survival following BRAFi.